An astonishing story in this week’s news starkly illustrates the value of quality approaches, and the implications of the failure to implement them, more than any I have seen in recent times.
Against the backdrop of huge spending cuts in the public sector, a survey of NHS health trusts has revealed that the NHS is missing out on millions of pounds for the reimbursement of cancer drugs because of onerous paperwork.
Schemes for the NHS to share the cost of expensive new drugs with pharmaceutical companies have become increasingly common but a survey of 31 English health trusts published this week revealed that up to 50% of the costs had not been recovered due to the bureaucratic complexity of the process.
One consultant pharmacist demonstrated the system’s failure most succinctly by welcoming the wider access to new cancer drugs but adding that the reimbursement procedures were so onerous as to make the whole scheme unworkable.
Although benefitting from budget ring-fencing for the moment at least, the NHS, like all other parts of the public sector, is coming under pressure to both innovate and save costs so what does this say about its ability to do both?
When questioned about how the system could be devised to work better, users say that only relatively small changes need to be made, citing the need for form templates and greater flexibility on timescales. Yet, because process users presumably weren’t consulted about the process in the first place, the future of this ground-breaking government and private sector partnership is being threatened.
As the survey author says, the implications are enormous, not only in terms of potentially unclaimed assets for the NHS but the misuse of staff time and the threat to the future access of patients to the best drugs on the market.
In response to the survey, a Department of Health spokesman said it continued to work with the pharmaceutical industry to make the schemes as easy as possible to implement but put the onus back on the primary care trusts to make individual arrangements on how to deal with the issue of reimbursement.
The difference between those that will succeed and those that will fail will of course be down to their willingness and ability to deploy basic quality management approaches and techniques such as those identified in Deming’s PDSA. It will be interesting to see how many of them can rise to the quality challenge.
Simon Feary
Chief Executive Officer
28 July 2010


